How to ask and what to do: A guide for clinical inquiry and intervention regarding female sexual health after cancer

Current Opinion in Supportive and Palliative Care

Volumn 10, Issue 1, 2016, Pages 44-54

  Bober, Sharon L ^a   Reese, Jennifer B ^b   Barbera, Lisa ^c   Bradford, Andrea ^d   Carpenter, Kristen M ^e   Goldfarb, Shari ^f,g   Carter, Jeanne ^f,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer; provider communication; sexual health

Indexed keywords

CANCER SURVIVOR; CHECKLIST; FEMALE; HUMAN; HUMAN EXPERIMENT; MODEL; ONCOLOGY; PATIENT EDUCATION; PATIENT REFERRAL; SEXUAL HEALTH; HUMAN RELATION; INTERPERSONAL COMMUNICATION; NEOPLASM; PSYCHOLOGY; REPRODUCTIVE HEALTH; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SURVIVOR; WOMEN'S HEALTH;

COMMUNICATION; FEMALE; HUMANS; INTERPERSONAL RELATIONS; NEOPLASMS; PATIENT EDUCATION AS TOPIC; REPRODUCTIVE HEALTH; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SURVIVORS; WOMEN'S HEALTH;

EID: 84957646581     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000186     Document Type: Review

References (69)

1. Juraskova I, Butow P, Robertson R, et al. Posttreatment sexual adjustment following cervical and endometrial cancer: a qualitative insight. Psychooncology 2003; 12:267-279.
2. Katz A. The sounds of silence: sexuality information for cancer patients. J Clin Oncol 2005; 23:238-241.
3. Landmark BT1, Bøhler A, Loberg K, Wahl AK. Women with newly diagnosed breast cancer and their perceptions of needs in a health-care context. J Clin Nurs 2008; 17:192-200.
4. Hewitt M, Greenfield S, Stovall E, editors. Cancer patient to cancer survivor: lost in transition. Washington, DC: Institute of Medicine and National Research Council; 2005.
5. Ussher JM, Perz J, Gilbert E, et al. Talking about sex after cancer: a discourse analytic study of healthcare professional accounts of sexual communication with patients. Psychol Health 2013; 28:1370-1390.
6. Flynn KE, Reese JB, Jeffery DD, et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology 2012; 21:594-601.
7. Hordern AJ, Street AF. Let's talk about sex: risky business for cancer and palliative care clinicians. Contemp Nurse 2007; 27:49-60.
8. Hordern AJ, Street AF. Communicating about patient sexuality and intimacy after cancer: mismatched expectations and unmet needs. Med J Aust 2007; 186:224-227.
9. Bober SL, Recklitis CJ, Campbell EG, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer 2009; 115 (18 Suppl):4409-4418.
10. Wiggins DL, Wood R, Granai CO, Dizon DS. Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO). J Psychosoc Oncol 2007; 25:61-70.
11. Park ER, Norris RL, Bober SL. Sexual health communication during cancer care: barriers and recommendations. Cancer J 2009; 15:74-77.
12. Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003; 88:666-671.
13. Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med 2010; 7:1139-1146.
14. Hordern AJ, Street AF. Constructions of sexuality and intimacy after cancer: patient and health professional perspectives. Soc Sci Med 2007; 64:1704-1718.
15. Ananth H1, Jones L, King M, Tookman A. The impact of cancer on sexual function: a controlled study. Palliat Med 2003; 17:202-205.
16. Gilbert E, Ussher JM, Perz J. Embodying sexual subjectivity after cancer: a qualitative study of people with cancer and intimate partners. Psychol Health 2013; 28:603-619.
17. Tsai YF. Nurses' facilitators and barriers for taking a sexual history in Taiwan. Appl Nurs Res 2004; 17:257-264.
18. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26:191-208.
19. Yi JC, Syrjala KL. Sexuality after hematopoietic stem cell transplantation. Cancer J 2009; 15:57-64.
20. Jeffery DD, Barbera L, Andersen BL, et al. Self-reported sexual function measures administered to female cancer patients: a systematic review, 2008-2014. J Psychosoc Oncol 2015; 33:433-466.
21. Flynn KE, Lin L, Cyranowski JM, et al. Development of the NIH PROMIS1 Sexual Function and Satisfaction measures in patients with cancer. J Sex Med 2013; 10 (Suppl 1):43-52.
22. Hatzichristou D, Rosen RC, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004; 1:49-57.
23. Goldfarb SB, Abramsohn E, Andersen BL, et al. A national network to advance the field of cancer and female sexuality. J Sex Med 2013; 10:319-325.
24. Annon JS. The PLISSIT model: a proposed conceptual scheme for the behavioral treatment of sexual problems. A J Sex Educ Ther 1976; 2:1-15.
25. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011; 8:549-559.
26. Deci EL, Ryan RM. Self-determination theory in healthcare and its relations to motivational interviewing: a few comments. Int J Behav Nutr Phys Act 2012; 9:24.
27. Barbera L, Fitch M, Adams L, et al. Improving care for women after gynecological cancer: the development of a sexuality clinic. Menopause 2011; 18:1327-1333.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Association; 2000. Text Revision (DSM-IV-TR).
29. Lowenstein L, Gruenwald I, Gartman I, Vardi Y. Can stronger pelvic muscle floor improve sexual function? Int Urogynecol J 2010; 21:553-556.
30. Billups KL, Berman L, Berman J, et al. A new nonpharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001; 27:435-441.
31. Schroder M, Mell LK, Hurteau JA, et al. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys 2005; 61:1078-1086.
32. Schover LR. Sexuality and fertility after cancer. Hematology Am Soc Hematol Educ Program 2005; 2005:523-527.
33. Gahm J, Hansson P, Brandberg Y, Wickman M. Breast sensibility after bilateral risk-reducing mastectomy and immediate breast reconstruction: a prospective study. J Plast Reconstr Aesthet Surg 2013; 66:1521-1527.
34. Peled AW, Duralde E, Foster RD, et al. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expanderimplant reconstruction. Ann Plast Surg 2014; 72 (Suppl 1):S48-S52.
35. Shridharani SM, Magarakis M, Stapleton SM, et al. Breast sensation after breast reconstruction: a systematic review. J Reconstr Microsurg 2010; 26:303-310.
36. Gagnon JH, Rosen RC, Leiblum SR. Cognitive and social aspects of sexual dysfunction: sexual scripts in sex therapy. J Sex Marital Ther 1982; 8:44-56.
37. American College of Obstetricians and Gynecologist Task Force on Hormone Therapy. Sexual dysfunction. Obstet Gynecol 2004; 104 (4 Suppl):85S-91S.
38. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005; 88:222-228.
39. Chen J, Geng L, Song X, et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med 2013; 10:1575-1584.
40. Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, noncontrolled clinical trial. Eur Rev Med Pharmacol Sci 2008; 12:411-416.
41. Ekin M, Yaşar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 2011; 283:539-543.
42. van der Laak JA, de Bie LM, de Leeuw H, et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol 2002; 55:446-451.
43. Memorial Sloan Kettering Cancer Center Clinical Trial. Serum estradiol levels in post menopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogen. NCT00984300. 2009. http://www. Clinical-Trials. gov. [Accessed September 26, 2010]
44. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004; 96:1856-1865.
45. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health 2010; 1:105-111.
46. Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011; 17:403-408.
47. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33:3394-3400.
48. Stratton P, Turner ML, Childs R, et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol 2007; 110:1041-1049.
49. Shanis D, Merideth M, Pulanic TK, et al. Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. Semin Hematol 2012; 49:83-93.
50. Spinelli S, Chiodi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003; 88:1163-1168.
51. Zantomio D, Grigg AP, MacGregor L, et al. Female genital tract graft-versushost disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006; 38:567-572.
52. Bradford A, Nebgen D, Keeler E, Milbourne A. A comprehensive program to meet the sexual health needs of women with cancer. Seventh Biennial Cancer Survivorship Research Conference, Atlanta, GA; June 2014.
53. Elder EE, Brandberg Y, Bjö rklund T, et al. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast 2005; 14:201-208.
54. Manderson L. Boundary breaches: the body, sex and sexuality after stoma surgery. Soc Sci Med 2005; 61:405-415.
55. Rosenberg SM, Tamimi RM, Gelber S, et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer 2014; 120:2264-2271.
56. Bober SL, Recklitis CJ, Bakan J, et al. Addressing sexual dysfunction after riskreducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med 2015; 12:189-197.
57. Laumann EO, Glasser DB, Neves RC, et al. A population-based survey of sexual activity, sexual problems and associated help-seeking behavior patterns in mature adults in the United States of America. Int J Impot Res 2009; 21:171-178.
58. Simons JS, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001; 30:177-219.
59. Moreira ED Jr, Brock G, Glasser DB, et al. Help-seeking behaviour for sexual problems: the global study of sexual attitudes and behaviors. Int J Clin Pract 2005; 59:6-16.
60. Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112:970-978.
61. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 23:762-774.
62. Segraves RT, Balon R. Sexual pharmacology: fast facts. New York: WW Norton; 2003.
63. Scott JL, Kayser K. A review of couple-based interventions for enhancing women's sexual adjustment and body image after cancer. Cancer J 2009; 15:48-56.
64. MacPhee DC, Johnson SM, Van der Veer MM. Low sexual desire in women: the effects of marital therapy. J Sex Marital Ther 1995; 21:159-182.
65. Brotto LA, Erskine Y, Carey M, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012; 125:320-325.
66. Frü hauf S, Gerger H, Schmidt HM, et al. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav 2013; 42:915-933.
67. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012; 9:1134-1148.
68. Heiman JR. Treating low sexual desire: new findings for testosterone in women. N Engl J Med 2008; 359:2047-2049.
69. Food and Drug Administration Joint Meeting of Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Fibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. NDA 022526. Advisory Committee Briefing Document. 2015.